FCF Biotech
Venture Capital Monitor

The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.

FCF Biotech Venture Capital Monitor - USA

As of the end of December 2022, we identify the following current VC trends in the US-Biotech sector:

  • In 2022, overall Biotech funding in the USA has reached USD 31,894m (-1,027m compared to 2021)
  • The top 5 deals exceed USD 340m each, largest transaction amounted to USD 3,000m in Altos Labs
  • ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by OrbiMed (USA) and RA Capital Management (USA)
  • Oncology dominates as the top indication

Capital Markets Research

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications: